SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature

TY - JOUR

T1 - SARS-CoV-2 vaccination and new-onset myasthenia gravis

T2 - A report of 7 cases and review of the literature

AU - Ramdas, Sithara

AU - Hum, Ryan Malcolm

AU - Price, Abigail

AU - Paul, Anna

AU - Bland, Jeremy

AU - Burke, Georgina

AU - Farrugia, Maria

AU - Palace, Jacqueline

AU - Storrie, Alice

AU - Ho, Pauline

AU - Standing, Emma

AU - Lilleker, James B.

AU - Jungbluth, Heinz

N1 - Funding Information: We would like to thank all the patients for allowing us to publish this manuscript. We would like to thank Professor Tracey Willis (Oswestry, United Kingdom) and the Muscle Interest Group (MIG) of the United Kingdom for facilitating and supporting this work. Publisher Copyright: © 2022

PY - 2022/10

Y1 - 2022/10

N2 - Myasthenia gravis (MG) is an antibody-mediated immune disorder of the neuromuscular junction. SARS-CoV-2 is now recognised as a trigger factor for autoimmune diseases and to cause immune-mediated dysregulation, likely due to molecular mimicry induced by viral antigens. SARS-CoV-2 vaccination, similarly, results in exposure to viral antigen. Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.

AB - Myasthenia gravis (MG) is an antibody-mediated immune disorder of the neuromuscular junction. SARS-CoV-2 is now recognised as a trigger factor for autoimmune diseases and to cause immune-mediated dysregulation, likely due to molecular mimicry induced by viral antigens. SARS-CoV-2 vaccination, similarly, results in exposure to viral antigen. Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered (auto)immunity following SARS-CoV-2 vaccination and/or infection.

KW - Myasthenia gravis

KW - SARS-CoV-2

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85138582756&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2022.09.001

DO - 10.1016/j.nmd.2022.09.001

M3 - Article

C2 - 36130855

AN - SCOPUS:85138582756

SN - 0960-8966

VL - 32

SP - 785

EP - 789

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

IS - 10

ER -